OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Petrylak on Future Research in Prostate Cancer

October 22nd 2020

Daniel P. Petrylak, MD, discusses future research in prostate cancer.

Dr. Nagle on the Evolution of Daratumumab Administration in Multiple Myeloma

October 22nd 2020

Sarah Nagle, MD, discusses the evolution of daratumumab administration in multiple myeloma.

Dr. Tolaney on Data With Trastuzumab Deruxtecan in HER2+ Breast Cancer Brain Metastases

October 22nd 2020

Sara M. Tolaney, MD, MPH, discusses the potential role of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and brain metastases.

Dr. Grothey on Combination Therapies with Regorafenib and TAS-102 in CRC

October 22nd 2020

Axel Grothey, MD, discusses combination therapies with regorafenib and trifluridine/tipiracil in colorectal cancer.

Dr. Skarbnik on Treatment Considerations in CLL

October 22nd 2020

Alan P. Z. Skarbnik, MD, discusses treatment considerations in chronic lymphocytic leukemia.

Dr. Schwartz on the Benefit of Dose Reduced Nivolumab/Ipilimumab in Metastatic Sarcomas

October 22nd 2020

Gary K. Schwartz, MD, discusses the benefit of dose reducing ipilimumab plus nivolumab in metastatic sarcomas.

Dr. Abraham on Remaining Questions With Pexidartinib in TGCT

October 21st 2020

John A. Abraham, MD, FACS, discusses remaining questions with pexidartinib in tenosynovial giant cell tumor.

Dr. D’Amato on the Limitations of Liquid Biopsy in Sarcoma

October 21st 2020

Gina Z. D'Amato, MD, discusses the limitations of liquid biopsy in sarcoma.

Dr. Maki on the Utility of IDH1/2 Inhibitors in Chondrosarcoma

October 21st 2020

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the utility of IDH1/2 inhibitors in chondrosarcoma.

Dr. Halfdanarson on the Evolving Role of Immunotherapy in CRC

October 21st 2020

Thorvardur Halfdanarson, MD, discusses the evolving role of immunotherapy in colorectal cancer.

Dr. Azad on Future Research Efforts in CRC

October 21st 2020

Nilofer Saba Azad, MD, discusses future research efforts in colorectal cancer.

Dr. Hill on the Impact of the COVID-19 Pandemic in MCL

October 21st 2020

Brian T. Hill, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on patients with mantle cell lymphoma.

Dr. McDermott on Preventing Recurrence of High-Risk Prostate Cancer

October 21st 2020

Ray McDermott, discusses preventing recurrence in patients with very high-risk prostate cancer.

Dr. Hussain on Meaningful Effect as an End Point in Prostate Cancer Trials

October 21st 2020

Maha Hussain, MD, FACP, FASCO, discusses the importance of meaningful effect in prostate cancer trials.

Dr. Bhat on ELEVATE-TN Results in Treatment-Naïve CLL

October 21st 2020

Seema A. Bhat, MD, discusses the results of the phase 3 ELEVATE-TN trial in patients with treatment-naïve CLL.

Dr. Lwin on the Design of the LEAP-005 Trial in Pretreated Advanced Solid Tumors

October 20th 2020

Zarnie Lwin, MBBS, FRACP, discusses the design of the phase 2 LEAP-005 trial in previously treated patients with advanced solid tumors.

Dr. Skarbnik on Frontline Treatment Considerations in CLL

October 20th 2020

Alan P. Z. Skarbnik, MD, discusses frontline treatment considerations in chronic lymphocytic leukemia.

Dr. Abraham on the Clinical Utility of Pexidartinib in TGCT

October 20th 2020

John A. Abraham, MD, FACS, discusses the clinical utility of pexidartinib in tenosynovial giant cell tumor.

Dr. Hill on the FDA Approval of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

October 20th 2020

Brian T. Hill, MD, PhD, discusses the FDA approval of brexucabtagene autoleucel for patients with relapsed/refractory mantle cell lymphoma.

Dr. Ocean on Determining Optimal Frontline Treatments for Metastatic Pancreatic Cancer

October 20th 2020

Allyson Ocean, MD, discusses determining the optimal frontline treatment of patients with metastatic pancreatic cancer.